AboleIIs Pharma

Phase 1

Gosselies, BelgiumFounded 2019aboleris-pharma.com

AbolerIS Pharma, founded in 2019, is a Belgian-French biotech focused on transforming the treatment of autoimmune diseases and transplant rejection through immune tolerance restoration. The company's core technology targets the CD45RC marker to selectively deplete pathogenic effector T and B cells while sparing regulatory T cells, aiming for long-term, drug-free remission. Backed by notable European life science VCs and having secured non-dilutive grants, AbolerIS has advanced its lead candidate ABO21009 into Phase 1 clinical trials, with initial data demonstrating a novel and potentially safer mechanism of action.

Founded

2019

Focus

AntibodiesBiologics

AI Company Overview

Technology Platform

A monoclonal antibody platform targeting the CD45RC isoform to selectively deplete pathogenic effector T and B cells while preserving regulatory T cells and immune memory, aiming to restore immune tolerance without broad immunosuppression.

Opportunities

The broad applicability of the CD45RC target across multiple high-value autoimmune and transplant indications presents a significant pipeline-in-a-product opportunity.

Successful proof-of-concept in the ongoing RA trial could unlock expansion into large markets like IBD and pave the way for partnerships in transplantation.

The growing unmet need for curative-intent therapies in immunology creates a receptive market for a successful tolerance-inducing agent.

Risk Factors

The primary risk is the unproven clinical safety and efficacy of this first-in-class mechanism in humans.

The company faces intense competition from established and novel immunomodulators and is dependent on future fundraising in a challenging biotech capital environment.

Demonstrating clear differentiation and superior therapeutic benefit will be critical for commercial success.

Competitive Landscape

AbolerIS competes with broad immunosuppressants (e.g., anti-TNFs, JAK inhibitors), selective cell depleters (e.g., anti-CD20), and emerging Treg-focused therapies. Its key differentiation is the precise targeting of the CD45RC marker to selectively deplete only pathogenic immune cells while sparing and expanding regulatory cells, aiming for a superior safety and efficacy profile that enables long-term, drug-free remission.